港股異動 | 康方生物-B(9926.HK)漲約4% 自主研發腫瘤藥人體臨牀研究有進展
格隆匯11月12日丨康方生物-B(9926.HK)漲約4%,報24港元,總市值189億港元。康方生物公佈,公司已於第35屆腫瘤免疫治療學會年會(「SITC 2020」)發佈其自主研發CD47單抗(研發代號:AK117)的首次人體臨牀研究進展。AK117是次臨牀研究用於治療復發或難治性的晚期或轉移性實體瘤或淋巴瘤,目前AK117正在澳洲開展劑量遞增臨牀試驗,在已完成的低劑量受試者給藥試驗中,均未發生藥物相關的貧血症狀和無與治療相關的3級或以上不良事件;各隊列受試者對藥物耐受性良好,無劑量限制性毒性(DLT)事件發生,是下一代腫瘤免疫治療的熱門靶點。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.